In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior ... positive), and immunosuppressive treatment (cyclophosphamide or rituximab, assigned at the discretion ...

A single-cell analysis of nearly 18,000 white blood cells identifies a unique neutrophil subset characterized by type II ...

Prophylactic trimethoprim-sulfamethoxazole lowered serious infection risk in patients with ANCA-associated vasculitis, ...

In the largest study to date of 71 patients with refractory or relapsing ANCA-associated vasculitis, 65% achieved clinical remission with alemtuzumab treatment and a further 20% of patients had a ...

Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the ...

ANCA-associated vasculitis was officially designated an intractable disease by the MHLW. Intractable diseases are rare diseases for which no effective treatment exists but for which long-term ...

Talk to your doctor before making any changes to your treatment plan. You have anti-neutrophil cytoplasmic antibodies (ANCA). If you have lupus associated with ANCA your risk for vasculitis is higher.

The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain COPD patients whose disease isn't ...

The ANCA test can be helpful for diagnosing vasculitis if you have symptoms like these: The ANCA test can also show if the treatment you take for vasculitis is working. And your doctor can use it ...

Abbreviations: AAV, ANCA-associated vasculitis; EULAR, European League Against Rheumatism; EUVAS, European Vasculitis Study Group. The gold-standard treatment for remission maintenance is 2 mg/kg ...